Starpharma Holdings Limited (SPHRY)

Market Cap	23.81M
Revenue (ttm)	2.57M
Net Income (ttm)	-7.75M
Shares Out	n/a
EPS (ttm)	-0.02
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	4,000
Average Volume	685
Open	0.5900
Previous Close	0.5900
Day's Range	0.5900 - 0.6200
52-Week Range	0.5200 - 0.9200
Beta	0.61
RSI	44.11
Earnings Date	May 26, 2025

About Starpharma Holdings

Starpharma Holdings Limited, a biopharmaceutical company, engages in the research, development, and commercialization of dendrimer products for pharmaceutical, life science, and other applications worldwide. The company’s products include VivaGel BV, a non-antibiotic vaginal gel for the treatment of bacterial vaginosis (BV) and prevention of recurrent BV; VIRALEZE, an antiviral nasal spray; and VivaGel condom, an antiviral condom coating. It is also involved in the development of dendrimer enhanced product (DEP) delivery platform, consisting of...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1997
• Employees: 40
• Stock Exchange: OTCMKTS
• Ticker Symbol: SPHRY

Financial Performance

In 2024, Starpharma Holdings's revenue was 9.76 million, an increase of 124.64% compared to the previous year's 4.34 million. Losses were -8.17 million, -47.79% less than in 2023.

Financial numbers in AUD